Limited coverage drugs – budesonide nebules
Last updated on October 24, 2022
|
Generic name |
budesonide |
|---|---|
|
Strength |
0.125 mg/mL, 0.25 mg/mL, 0.25 mg/2mL, 0.5 mg/mL, 0.5 mg/2 mL, 1.0 mg/2 mL |
| Form | nebule and solution |
|
Special Authority criteria |
Approval period |
|---|---|
| 1. Person who has cognitive impairment PLUS has had an unsuccessful trial in the use of an inhaler attached to an aerochamber with a mouthpiece.
OR 2. Person who is living independently PLUS either suffers from severe upper extremity disability or lacks fine motor co-ordination to a degree that precludes effective inhaler techniques, even when aided by inhaler-assistance devices. OR 3. Resident of a long-term care facility PLUS regularly requires the administration of three or more inhaled medications at least three times daily. OR 4. Person who has difficulty generating adequate inspiratory effort that they are unable to achieve therapeutic benefit from an inhaler with an aerochamber. |
Indefinite
|
Practitioner exemptions
- None
Special notes
- Special Authority is not required for individuals 18 years and younger.
Special Authority requests